OKYO Pharma Moves At-The-Market Equity Offering Facility To Leerink
OKYO Pharma Limited +4.43%
OKYO Pharma Limited OKYO | 1.65 | +4.43% |
The ATM facility provides OKYO Pharma the ability to raise capital opportunistically while minimizing market disruption. Sales under the program, if any, will be made pursuant to a prospectus supplement and accompanying base prospectus filed with the U.S. Securities and Exchange Commission (SEC). Leerink Partners will act as the exclusive sales agent and receive a commission equal to 3.0% of gross proceeds from any shares sold.
